Full history for every metric is available with a Kvantra account
Oyster Point Pharma, Inc. (OYST)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 25 | 20 |
| Operating profit | $m | -97 | -164 | |||||
| Net profit | $m | - | -7 | -17 | -46 | -71 | -104 | -189 |
| EPS reported | $ | -4.01 | -7.11 | |||||
| Operating cashflow per share | $ | -3.43 | -3.43 | |||||
| Capex per share | $ | 0.06 | 0.06 | |||||
| FCF per share | $ | -3.49 | -3.49 | |||||
| Free cash flow | $m | -91 | -166 | |||||
| Net debt | $m | -101 | 23 | |||||
| Book value equity | $m | 100 | -22 | |||||
| Book value per share | $ | 3.82 | -0.83 | |||||
| Number of shares | m | 26.04 | 26.83 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.78 | -13.50 | |||||
| P/S LTM | x | 19.38 | 15.30 | |||||
| P/FCF LTM | x | -5.23 | -1.80 | |||||
| EV/EBITDA LTM | x | -3.87 | -1.97 | |||||
| EV/Sales LTM | x | 15.27 | 16.50 | |||||
| Earnings Yield LTM | % | -21.96% | -35.89% | |||||
| FCF Yield | % | -19.11% | -55.53% | |||||
| Quality | ||||||||
| ROE | % | -104.88% | -72.95% | |||||
| ROIC | % | -49.80% | -49.80% | |||||
| Operating margin | % | -394.98% | -394.98% | |||||
| Gross margin | % | 93.79% | 93.79% | |||||
| FCF/Sales | % | -370.25% | -370.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | +9.15% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.98 | -1.76 | |||||
| Net Debt/EBITDA | x | 1.04 | 1.04 | |||||
| EBIT/Net interest | x | -25.96 | -25.96 | |||||
| Net debt/market cap | % | -21.17% | 7.81% | |||||
| Net debt/Equity | x | -1.01 | -1.05 | |||||
| Gross debt/equity | x | 0.93 | -4.27 | |||||
Company overview
Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease. TYRVAYA is also being evaluated in a Phase II clinical trial for its potential application in treating neurotrophic keratopathy. Oyster Point Pharma was founded in 2015 and was headquartered in Princeton, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oyster Point Pharma, Inc. (OYST)
Viatris Inc. completed its acquisition of Oyster Point Pharma, Inc. on January 3, 2023. Prior to this, Oyster Point Pharma operated as a commercial-stage biopharmaceutical firm, primarily focused on discovering, developing, and commercializing pharmaceutical treatments for various eye conditions within the United States. The company's principal investigational therapy is TYRVAYA, a nicotinic acetylcholine receptor agonist designed to alleviate the signs and symptoms of dry eye disease. TYRVAYA is also being evaluated in a Phase II clinical trial for its potential application in treating neurotrophic keratopathy. Oyster Point Pharma was founded in 2015 and was headquartered in Princeton, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free